7-Oxodehydroepiandrosterone 3-Acetate Conium Macul
| Evidence Level: L5 | Predicted Indications: 0 |
Table of Contents
- 7-Oxodehydroepiandrosterone 3-Acetate Conium Macul
- Multi-component Mixture (Containing Somatropin and 11 Other Ingredients): Indication Unknown, TxGNN Unable to Predict
Multi-component Mixture (Containing Somatropin and 11 Other Ingredients): Indication Unknown, TxGNN Unable to Predict
One-Sentence Summary
This formulation is a mixed composition of 12 heterogeneous components, comprising homeopathic raw materials (such as Conium maculatum, Lycopodium, Sepia officinalis), glandular extracts (porcine adrenal and pituitary), and growth hormone (somatropin), with no approved market records in either the United States or Taiwan. Due to the extremely complex component combination and known toxicity of certain ingredients, the TxGNN model generated no predicted indications, and available data are insufficient to support drug repurposing assessment.
Quick Overview
| Item | Content |
|---|---|
| Original Approved Indication | Unknown (No market approval record) |
| Predicted New Indications | None (TxGNN did not generate predictive results) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (Model query only, no predictive output; actually below L5) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold (Pending) |
Why is This Prediction Reasonable?
This formulation is composed of 12 highly heterogeneous components and cannot be described by a single pharmacological mechanism; the TxGNN knowledge graph model consequently failed to match effective disease node associations and generated no predicted indications. This section is instead devoted to explaining the known pharmacological background of the formulation’s composition.
Some components have relatively clear pharmacological effects: somatropin (recombinant human growth hormone) is an approved prescription drug used for growth hormone deficiency; DHEA derivatives (7-oxo DHEA acetate) have been investigated for metabolic regulation; selenium (Selenium) and silicon (Silicon dioxide) are trace micronutrients. However, Conium maculatum (poison hemlock, containing coniine alkaloids) and hydrofluoric acid (Hydrofluoric acid) both have significant toxicity at non-homeopathic doses and require strict dosage and safety clarification when included as formulation components.
The remaining components—Lycopodium clavatum, Sepia officinalis, and oyster shell calcium carbonate—are all traditional homeopathic materials that lack high-quality clinical evidence in conventional pharmacology literature. Overall, the action mechanism and indication of this compound formulation are unclear, and it cannot support rational derivation of drug repurposing.
Clinical Trial Evidence
Currently no related clinical trial registration records.
(TxGNN did not output predicted indications, making it impossible to associate specific diseases for clinical trial retrieval.)
Literature Evidence
Currently no relevant literature data available for citation.
US Market Information
No market approval records of any kind. Query results show that this multi-component mixture has no NDA or corresponding approval certificate in the United States (or Taiwan).
Safety Considerations
Key Safety Warnings (Based on Known Component Toxicology):
- Conium maculatum (poison hemlock): Contains coniine and γ-coniceine, which are potent nicotinic acetylcholine receptor antagonists that can lead to ascending motor paralysis and respiratory muscle paralysis. Even at extremely low homeopathic doses, its safety margin remains of concern to toxicologists.
- Hydrofluoric Acid: Has strong corrosive properties and can penetrate tissues and chelate calcium and magnesium ions, causing systemic toxicity such as hypocalcemia and arrhythmias. As a formulation component, it requires clear dilution ratios and safety data.
- Somatropin (growth hormone): Is a controlled prescription drug; unauthorized use may lead to serious adverse events such as acromegaly, glucose intolerance, and increased intracranial pressure; has known drug interactions with insulin and glucocorticoids.
- Sus scrofa glandular extracts (porcine adrenal and pituitary): Belong to glandular therapy raw materials with potential risk of transmission of zoonotic pathogens and must comply with TSE/BSE regulatory requirements.
Due to safety data gaps (Blocking level), currently unable to complete S1 safety preliminary assessment. It is recommended that no clinical application assessment be undertaken before obtaining complete product information or toxicology data.
Conclusion and Next Steps
Decision: Hold (Pending)
Rationale: This formulation faces three concurrent obstacles: (1) TxGNN model failed to generate any predicted indications; (2) contains components with known toxicity (poison hemlock, hydrofluoric acid) with Blocking-level safety data gaps; (3) has no market approval record in the United States, and market feasibility is unclear. Drug repurposing assessment should not proceed before these issues are resolved.
The following data must be completed before proceeding:
- Safety Data (Blocking): Obtain complete component dilution ratios, toxicology research reports, and product information warnings; clarify whether the actual doses of Conium maculatum and hydrofluoric acid reach toxicity thresholds
- Formulation Characterization: Confirm whether this is a homeopathic formulation, a glandular therapy formulation, or a complex prescription drug, to determine the applicable regulatory pathway (NDA vs. OTC Monograph vs. HMPC)
- Somatropin Component Compliance: Confirm whether growth hormone exists at pharmacologically active doses; if so, must separately apply for biologic license approval
- TxGNN Re-query: Divide the 12 components into individual active pharmaceutical ingredients (APIs) and conduct separate TxGNN predictions to obtain meaningful drug repurposing candidates
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.